BTAI +10%: SERENITY Phase 3 Safety Win Sets Up Q1 2026 sNDA as BioXcel Targets 57-77M At‑Home Episodes

BioXcel Therapeutics (NASDAQ:BTAI) jumped about 10% after the company disclosed that its SERENITY At-Home Phase 3 safety study hit its primary endpoint - a clear green flag on tolerability that underpins a planned supplemental NDA to expand IGALMI's label.

The trial tested BXCL501, BioXcel's sublingual film formulation of dexmedetomidine, for treating agitation episodes in patients with bipolar disorder or schizophrenia outside of hospitals. The 120 mcg dose was well tolerated over repeated use across the 12-week study. Not a single discontinuation in the BXCL501 arm was attributed to tolerability, and the adverse event pattern matched what's already on IGALMI's label from institutional use.

Quick stats: 246 patients recorded 2,628 agitation episodes; 2,437 of those episodes were treated across 208 patients. Early exploratory signals also pointed to regular reductions in agitation and a higher share of full symptom resolution versus placebo, although those are labeled exploratory.

BioXcel has said it intends to file an sNDA in Q1 2026 to enable outpatient, unsupervised use of IGALMI - today the product is FDA-approved only for medically supervised settings. Management argues there's a big unmet need at home, and they've substantially revised their market math: the company now pegs U.S. at-home agitation episodes at roughly 57-77 million a year, up from prior estimates near 23 million.

Why traders cared: a Phase 3 safety readout that supports a label-expansion filing lowers a regulatory uncertainty bucket - at least on the tolerability front - and materially increases the potential addressable market if the sNDA wins approval. That combination is why the shares reacted sharply on the news.

What's next on the timeline: the sNDA filing in early 2026 and whatever data the company releases to support outpatient efficacy and safety during regulatory review. Those items will likely set short- and medium-term catalysts for the stock.

All in all, the announcement reframes IGALMI from a hospital-only therapy toward a possible outpatient option, backed by a safety dataset the company says is consistent with prior institutional trials. How the market prices the expanded episode estimate and the upcoming regulatory path will be the story to watch.